How do treatments impact quality of life
A research team led by Arun Sanyal, M.D., director of Virginia Commonwealth Universitys Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, and Philip Newsome, Ph.D., of Kings College London, has been involved in the clinical trials exploring the potential of semaglutide the GLP-1 receptor agonist used for Wegovy and Ozempic to treat people with this type of liver disease
Arbutin: This is a milder pigment inhibitor than hydroquinone
Emotional Health and Sexual Desire Being overweight is linked to higher rates of depression, anxiety, and stress
It works by mimicking a natural hormone in your body that: Stimulates insulin release when blood sugar is high
The FDA also recommends that healthcare providers monitor all patients on GLP-1 medications during their treatment for changes in mood, suicidal thoughts, and new or worsening depression